Nobel Biocare announced today that its Board of Directors will propose that Franz Maier be elected as a Member of the Board at the next Annual General Meeting on 28 March 2013.
To drive the implementation of Nobel Biocare’s strategy, one of the priorities of the Board of Directors has been to broaden and strengthen its operational and management expertise, in particular in the area of medical technology and implant-based tooth restoration.
Franz Maier brings a successful track record of over 20 years in both functional and general management positions, most recently as an Executive Vice President Sales and Member of the Executive Board of Straumann in the medical devices and biotechnology industry. From 2007 until the end of 2012, he also served as a core committee member of the International Team for Implantology (ITI). Since 2012, Franz Maier has been the Founder and Principal of Summit Sherpas, a Board, CEO and Private Equity Advisory firm.
Rolf Watter, Chairman of Nobel Biocare: “The Board of Directors is pleased to propose that Franz Maier joins the Board. Mr. Maier possesses profound knowledge of our industry. With his excellent understanding of the business and his proven leadership in developing a sales organization that performed above market, he will be an ideal addition to help drive the execution of Nobel Biocare’s strategy - helping customers to treat more patients better.”
Concurrently to this nomination the Board of Directors received a proposal from one of its shareholders, Oskar K. Ronner (private investor, 68), for the election of three new board members at the next Annual General Meeting. Mr. Ronner proposes Cheryl Benini-Leland (Senior Vice President Siemens Schweiz AG Building Technologies Division), Rolf Renz (Chief Financial Officer & Executive Vice President Siemens Southwest Europe, 57) and himself to be elected by the Annual General Meeting.
The Nomination and Compensation Committee will interview these candidates and the Board of Directors will publish its recommendation in due course.
About Franz Maier
Mr. Maier (48, German native) joined Swiss med-tech company Straumann in July 2007 as an Executive Vice President Sales and Member of the Executive Board. Until his departure at the end of 2011, Mr. Maier made a significant contribution in developing the group to its current leading position in implant, regenerative and restorative dentistry. Prior to Straumann, Franz Maier worked for the Wella Group (since 2003 part of Procter & Gamble) for 14 years and held various managerial positions of increasing responsibility in Product Management, Strategic Management and Sales. He holds a Master of Science in Business Administration from Passau University in Germany.
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.